新型长效毒蕈碱拮抗剂revefenacin

Revefenacin: a novel long-acting muscarinic antagonist

revefenacin(商品名Yupelri■,曾用名TD-4208)是一种新型长效毒蕈碱拮抗剂,用于慢性阻塞性肺疾病患者的维持治疗,2018年11月9日由FDA批准上市,每日一次雾化治疗,方便有效地缓解症状。本文对revefenacin的作用机制、药效学、药动学、药物相互作用、临床评价和安全性进行综述。

Revefenacin(Yupelri■, TD-4208) is a novel long-acting muscarinic antagonist(LAMA) for maintenance therapy in patients with chronic obstructive pulmonary disease. It was approved by the FDA on November 9, 2018. Symptoms can be easily and effectively relieved by using revefenacin for atomization therapy only once daily. This article reviews the mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, clinical evaluation and safety of revefenacin.